Fabry Disease

Observational Study Protocol – Fabry Disease Registry

Protocol Name: Observational Study Protocol – Fabry Disease Registry Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

Observational Study Protocol – Fabry Disease Registry Read More »

Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease

Protocol Name: Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204

Randomized, open-label, Phase 3 study of the effect of venglustat on left ventricular mass index in Fabry disease Read More »

Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease (Amicus)

Protocol Name: A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease Sponsor: Amicus Indication: Fabry Disease Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease (Amicus) Read More »

Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain (Sanofi-Aventis)

Protocol Name: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Adult Participants With Fabry Disease (PERIDOT) Sponsor: Sanofi-Aventis Indication: Fabry Disease Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >

Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain (Sanofi-Aventis) Read More »